Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
Related Articles
- NIH to Consolidate Websites Under Nine Hubs Posted 09-18-2026
- FDA Warns Fresenius About Leaking PD Solution Bags and Particulates Posted 09-18-2026
- Somatus to Open Maryland Home Dialysis Training Center Posted 09-18-2026
- DaVita and Humana Partner to Care for 10,000 Medicare Advantage Members with CKD Posted 09-18-2026